Unlock AI-driven, actionable R&D insights for your next breakthrough.

Croscarmellose Sodium As A Pharmaceutical Excipient: Comprehensive Analysis Of Properties, Applications, And Formulation Strategies

NOV 17, 202664 MINS READ

Want An AI Powered Material Expert?
Here's Patsnap Eureka Materials!
Croscarmellose Sodium, a cross-linked polymer of carboxymethylcellulose sodium, has emerged as a critical pharmaceutical excipient with multifunctional capabilities extending beyond conventional disintegration. This superdisintegrant exhibits unique physicochemical properties that enable rapid tablet disintegration, enhanced drug dissolution, taste masking, and formulation stabilization across diverse therapeutic categories. Understanding its molecular architecture, performance parameters, and formulation interactions is essential for pharmaceutical scientists developing high-performance solid dosage forms with optimized bioavailability and patient compliance.
Want to know more material grades? Try Patsnap Eureka Material.

Molecular Structure And Physicochemical Characteristics Of Croscarmellose Sodium

Croscarmellose Sodium is fundamentally a cross-linked derivative of carboxymethylcellulose sodium, characterized by internal ether bridges that create a three-dimensional polymeric network 126. This cross-linking is achieved through self-crosslinking reactions in aqueous organic solvents catalyzed by sulfuric acid solutions, typically conducted in two-stage thermal processes: an initial reaction at 40–50°C for 0.5–2.0 hours followed by a secondary stage at 65–75°C for 2.0–4.0 hours 8. The degree of substitution (DS) of the precursor sodium carboxymethylcellulose critically influences the final product properties, with optimal DS values ranging from 0.60 to 0.85 for pharmaceutical-grade material 8.

The cross-linked architecture imparts several distinctive properties:

  • Rapid Water Uptake: The polymer exhibits exceptional hydrophilicity with rapid swelling capacity upon contact with aqueous media, expanding to several times its original volume within seconds 11.
  • Insolubility Profile: Unlike its linear precursor, Croscarmellose Sodium remains insoluble in water due to cross-linking, which prevents dissolution while maintaining swelling capability 12.
  • Particle Size Distribution: Pharmaceutical-grade material typically passes through 200-mesh sieves (approximately 75 μm), ensuring uniform distribution in tablet matrices 8.
  • Chemical Stability: The cross-linked structure provides resistance to enzymatic degradation and maintains integrity across physiological pH ranges (1.2–7.4) 612.

Commercial preparations are available under multiple trade names including Ac-Di-Sol® (FMC Corporation/Asahi Kasei), Primellose® (Avebe), Vivasol® (JRS), and DISOLCEL® (Mingtai Chemical), each with specific particle size distributions and swelling characteristics optimized for different formulation requirements 1214.

Mechanisms Of Action In Pharmaceutical Formulations

Disintegration Enhancement Through Croscarmellose Sodium

The superdisintegrant functionality of Croscarmellose Sodium operates through multiple synergistic mechanisms that collectively accelerate tablet breakdown:

Wicking Action: The hydrophilic carboxymethyl groups create capillary channels that draw water into the tablet matrix through capillary action, penetrating even hydrophobic drug particles 911. This wicking effect is particularly pronounced at concentrations above 6% w/w, where interconnected swelling networks form throughout the dosage form 913.

Swelling Pressure: Upon hydration, the polymer chains expand rapidly, generating internal mechanical stress that disrupts interparticulate bonds. Quantitative studies demonstrate that tablets containing 10–14% Croscarmellose Sodium achieve complete disintegration within 10–30 seconds in minimal water volumes 1113. This rapid disintegration is preserved even when the excipient is used as a coating material, distinguishing it from other superdisintegrants like crospovidone or sodium starch glycolate 511.

Deformation Recovery: The cross-linked structure exhibits elastic recovery after compression, creating internal stress points that facilitate fracture propagation during hydration 711.

Comparative evaluations reveal that Croscarmellose Sodium outperforms sodium starch glycolate (which develops ropy consistency limiting effectiveness) and crospovidone (which provides inadequate surface coverage) in granulation systems requiring rapid disintegration 11. The optimal concentration range for disintegration enhancement is 0.5–5% w/w for conventional applications, but specialized formulations may require 6–16% w/w to achieve specific dissolution profiles 4913.

Dissolution Rate Enhancement For Poorly Soluble APIs

Beyond simple disintegration, Croscarmellose Sodium significantly enhances dissolution rates of poorly soluble active pharmaceutical ingredients (APIs) through surface area maximization and microenvironmental pH modulation. Co-granulation of APIs with Croscarmellose Sodium at weight ratios of 5:1 (excipient:drug) or higher creates drug-excipient composites where API particles are deposited on the hydrophilic, strongly swelling superdisintegrant surface 7. This spatial arrangement prevents particle agglomeration and maintains high effective surface area for dissolution.

For tadalafil formulations, co-granulates containing Croscarmellose Sodium achieved superior dissolution without requiring micronization to d(0.9) values below 40 μm, demonstrating that the excipient's swelling and wetting properties can compensate for larger particle sizes 7. Similarly, entacapone and nitecapone formulations containing 8–16% Croscarmellose Sodium exhibited substantially increased release rates compared to formulations using conventional disintegrant concentrations 913.

The dissolution enhancement is particularly valuable for BCS Class II and IV compounds, where solubility limitations govern bioavailability. Formulation scientists should consider Croscarmellose Sodium concentrations of 10–20% w/w when developing immediate-release products for poorly soluble drugs, balancing dissolution benefits against potential impacts on tablet hardness and friability 37.

Stabilization Functions Of Croscarmellose Sodium In Drug Products

Chemical Stabilization Through Moisture Control

Croscarmellose Sodium functions as a stabilizing agent for moisture-sensitive APIs by controlling microenvironmental humidity within tablet matrices. This stabilization mechanism is particularly evident in formulations of 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid and its sodium salt, where Croscarmellose Sodium prevents hydrolytic degradation during storage 12612. The optimal mixing ratio of API to Croscarmellose Sodium for stabilization ranges from 10:1 to 1:20, with preferred ratios of 2:1 to 1:15 depending on the specific degradation pathway 16.

The stabilization effect likely results from:

  • Competitive Hydration: The excipient's high water affinity sequesters free moisture, reducing water activity at drug particle surfaces 12.
  • Physical Separation: The swollen polymer creates physical barriers between reactive drug molecules, limiting solid-state interactions 612.
  • pH Buffering: Residual carboxyl groups may provide localized pH buffering, protecting pH-sensitive functional groups 12.

Stability studies should evaluate Croscarmellose Sodium-containing formulations under ICH conditions (40°C/75% RH) for at least 6 months, monitoring both chemical purity and dissolution performance to ensure the stabilization benefit persists throughout shelf life 1612.

Incompatibility Considerations And Mitigation Strategies

Despite its widespread use, Croscarmellose Sodium exhibits documented incompatibilities with certain API classes, particularly those containing primary amine groups. DPP-4 inhibitors including linagliptin show degradation, extraction problems, or content uniformity issues when formulated with Croscarmellose Sodium without appropriate mitigation strategies 3. The primary amine functionality can undergo nucleophilic reactions with residual carboxyl groups or impurities in the excipient.

However, these incompatibilities can be overcome through formulation design:

Excipient Selection: Incorporating additional pharmaceutically acceptable excipients that physically separate the API from Croscarmellose Sodium or chemically neutralize reactive sites enables successful formulation 3. For linagliptin, formulations containing 10–20% Croscarmellose Sodium (by total weight) achieved required content uniformity when combined with appropriate diluents and binders 3.

Granulation Strategy: Wet granulation using Croscarmellose Sodium slurries as the granulating fluid, followed by immediate drying, minimizes contact time in the hydrated state where reactions are most likely 811. The slurry should contain only the water required for granulation (typically 2–15% of the API weight), and granulation time should be limited to prevent excessive Croscarmellose Sodium dissolution 11.

Quality Control: Pharmaceutical-grade Croscarmellose Sodium meeting national pharmacopoeia standards (USP, EP, JP, ChP) contains controlled levels of residual reactants and degradation products 8. Suppliers should provide certificates of analysis documenting pH (typically 5.0–7.0 for 1% aqueous dispersion), heavy metals (<10 ppm), and microbial limits.

Formulation Development Guidelines For Croscarmellose Sodium

Concentration Optimization For Different Dosage Forms

The optimal concentration of Croscarmellose Sodium varies significantly based on formulation objectives and manufacturing processes:

Immediate-Release Tablets (Conventional Disintegration):

  • Intragranular concentration: 0.5–2.0% w/w of total formulation weight 411
  • Extragranular concentration: 1.0–3.0% w/w of total formulation weight 411
  • Total concentration: 2.0–5.0% w/w provides adequate disintegration for most APIs 126

Rapid-Disintegration Tablets (Orally Disintegrating Tablets):

  • Total concentration: 6.0–16.0% w/w, preferably 10.0–14.0% w/w 913
  • Distribution: Primarily extragranular to maximize surface exposure to dissolution medium 11
  • Complementary excipients: Microcrystalline cellulose (10–50% w/w) and coprocessed MCC/calcium-sodium alginate complex (10–50% w/w) enhance suspension formation 11

Dissolution-Enhanced Formulations (Poorly Soluble APIs):

  • Co-granulation ratio: 5:1 to 20:1 (Croscarmellose Sodium:API) 7
  • Final tablet concentration: 10.0–20.0% w/w 37
  • Target drug loading: 2.0–10.0% w/w in final formulation 7

Stabilization Formulations (Moisture-Sensitive APIs):

  • Concentration: Adjusted to achieve API:Croscarmellose Sodium ratios of 2:1 to 1:15 1612
  • Distribution: Uniform throughout matrix to maximize moisture scavenging 12

Formulation scientists should conduct dissolution testing in multiple media (0.1N HCl, pH 4.5 acetate buffer, pH 6.8 phosphate buffer, water) to verify that Croscarmellose Sodium concentration provides adequate performance across physiological pH ranges 49.

Manufacturing Process Considerations

Wet Granulation with Croscarmellose Sodium Slurry:

This technique, detailed in patent literature 11, involves preparing a Croscarmellose Sodium slurry (2–15% of API weight) and using it as the granulating fluid. The process sequence is:

  1. Prepare Croscarmellose Sodium slurry in purified water (minimize preparation time to <30 minutes to prevent excessive dissolution) 11
  2. Granulate API and intragranular excipients using the slurry in high-shear or fluid-bed granulator 11
  3. Dry granules immediately to <2% moisture content using fluid-bed dryer at 40–60°C 811
  4. Mill dried granules through 1270 μm screen 4
  5. Blend with extragranular Croscarmellose Sodium, lubricants, and other excipients 11
  6. Compress into tablets at hardness levels that do not compromise disintegration (typically 4–8 kP for immediate-release products) 4

This method provides superior API coating with Croscarmellose Sodium compared to dry blending, enhancing both dissolution and content uniformity 11.

Direct Compression:

For moisture-sensitive APIs or heat-labile compounds, direct compression is preferred. Croscarmellose Sodium should be:

  • Screened through appropriate mesh (typically 40–60 mesh) to break up agglomerates 8
  • Blended with API and diluents using low-shear blending (V-blender or bin blender, 10–20 minutes) 3
  • Added in split portions (50–75% intragranular equivalent, 25–50% extragranular) if using roller compaction for pre-densification 4
  • Protected from excessive humidity during processing (maintain <40% RH in manufacturing areas) 16

Coating Applications:

Croscarmellose Sodium can be applied as a taste-masking coating via fluidized-bed coating processes 5. The coating suspension typically contains:

  • Croscarmellose Sodium: 5–20% w/w in aqueous vehicle 5
  • Plasticizer (optional): Polyethylene glycol 400 or propylene glycol at 10–30% of polymer weight 5
  • Process parameters: Inlet air temperature 40–60°C, spray rate 5–20 g/min, atomization pressure 1.5–2.5 bar 5

The resulting coated particles retain rapid disintegration properties while masking bitter taste during oral administration 5.

Applications Of Croscarmellose Sodium Across Therapeutic Categories

Cardiovascular And Metabolic Disease Formulations

Croscarmellose Sodium plays a critical role in formulations for cardiovascular and metabolic disorders, where rapid onset of action and consistent bioavailability are paramount.

Lipid-Modifying Agents: Formulations of 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid (a lipid-modifying compound) utilize Croscarmellose Sodium at 10:1 to 1:20 API ratios to achieve both chemical stabilization and enhanced dissolution 12612. The excipient prevents moisture-induced degradation of the dichlorinated fatty acid structure while accelerating release in gastric fluid. Typical formulations contain 60–90% w/w diluents (lactose, microcrystalline cellulose, mannitol), 3–6% w/w binders (hydroxypropylcellulose, povidone), and 2–5% w/w Croscarmellose Sodium 1612.

Antidiabetic Agents: Linagliptin, a DPP-4 inhibitor for type 2 diabetes, presents formulation challenges due to its primary amine group and low dose (5 mg). Despite initial concerns about incompatibility, formulations containing 10–20% w/w Croscarmellose Sodium successfully achieved content uniformity requirements without milling the API to submicron sizes 3. The high disintegrant concentration compensates for the low drug loading (typically 35–60% w/w in granules, 10–40% w/w in final tablets) and ensures uniform distribution throughout the dosage form 3. Dissolution testing should demonstrate >80% release within 30 minutes in pH 6.8 phosphate buffer to ensure adequate bioavailability.

Neurological Disorder Treatments

Parkinson's Disease Adjuncts: Entacapone and nitecapone, catechol-O-methyltransferase (COMT) inhibitors used as adjuncts to levodopa therapy, require rapid disintegration to achieve therapeutic plasma levels coinciding with levodopa administration 913. Formulations containing 8–16% w/w Croscarmellose Sodium (preferably 10–14% w/w) demonstrate substantially increased release rates compared to conventional 2–5% w/w formulations 913.

The enhanced dissolution is critical because:

  • Entacapone has a short elimination half-life (0.4–0.7 hours), requiring rapid absorption 913
  • The therapeutic window is narrow, necessitating consistent bioavailability 913
  • Patients often have difficulty swallowing, making rapid disintegration beneficial for compliance 13

Formulation composition typically includes entacapone or nitecapone (100–200 mg per tablet), Croscarmellose Sodium (10–14% w/w), microcrystalline cellulose as diluent (40

OrgApplication ScenariosProduct/ProjectTechnical Outcomes
KOWA COMPANY LTDCardiovascular and metabolic disease treatments requiring chemical stabilization of moisture-sensitive dichlorinated fatty acid compounds with enhanced bioavailability in gastric fluid.Lipid-Modifying Agent FormulationCroscarmellose sodium acts as stabilizing agent preventing moisture-induced degradation of 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid while enhancing dissolution rate at API:excipient ratios of 10:1 to 1:20, preferably 2:1 to 1:15.
SANOVEL ILAC SANAYI VE TICARET A.S.Type 2 diabetes treatment requiring uniform drug distribution in low-dose solid dosage forms (5mg) with consistent bioavailability and >80% dissolution within 30 minutes at pH 6.8.Linagliptin Tablet FormulationAchieved required content uniformity for low-dose DPP-4 inhibitor using 10-20% w/w croscarmellose sodium without API micronization, overcoming primary amine incompatibility through formulation design.
ORION CORPORATIONParkinson's disease adjunct therapy requiring rapid disintegration and consistent bioavailability to achieve therapeutic plasma levels coinciding with levodopa administration in patients with swallowing difficulties.Entacapone/Nitecapone TabletsSubstantially increased release rates using 8-16% w/w croscarmellose sodium (preferably 10-14% w/w) compared to conventional 2-5% formulations, enabling rapid absorption for short half-life APIs (0.4-0.7 hours).
SYNTHON BVErectile dysfunction treatment for BCS Class II poorly soluble APIs requiring enhanced dissolution and bioavailability without particle size reduction, maintaining 2-10% w/w drug loading in final formulation.Tadalafil Co-Granulate FormulationCo-granulation with croscarmellose sodium at 5:1 or higher weight ratios achieved superior dissolution without micronization to d(0.9) <40μm through drug deposition on hydrophilic swelling superdisintegrant surface.
FMC CORPORATIONOral suspension dosage forms for pediatric and geriatric patients requiring rapid tablet disintegration and uniform suspension formation with minimal agitation for both water-soluble and water-insoluble pharmaceuticals.Ac-Di-Sol Suspension TabletsRapid disintegration within 10-30 seconds in minimal water using 2-15% croscarmellose sodium slurry as granulating fluid, forming readily suspendible measured-dose formulations with 1-6% final disintegrant concentration.
Reference
  • Pharmaceutical composition comprising 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid
    PatentInactiveNZ534471A
    View detail
  • Medicinal composition containing 2,2-dichloro-12-(4-chlorophenyl) dodecanoic acid
    PatentInactiveHK1069772A
    View detail
  • Pharmaceutical formulations of linagliptin
    PatentActiveEP2853257A1
    View detail
If you want to get more related content, you can try Eureka.

Discover Patsnap Eureka Materials: AI Agents Built for Materials Research & Innovation

From alloy design and polymer analysis to structure search and synthesis pathways, Patsnap Eureka Materials empowers you to explore, model, and validate material technologies faster than ever—powered by real-time data, expert-level insights, and patent-backed intelligence.

Discover Patsnap Eureka today and turn complex materials research into clear, data-driven innovation!

Group 1912057372 (1).pngFrame 1912060467.png